ndmain.gif (7669 bytes)800.926.2906
Anti-AgingSpecialsArticlesManufacturingFDA+pH WaterHiro
spc1.gif (174 bytes)VitaminsHerbsMineralsAminoAcidsEnzymesHormones
spc2.gif (174 bytes)HomeopathicsXtra-CellGlandularsFatty AcidsTop ProductsTop Products
Health Function Guide
Natural Medicines
Library
Dr Morrow
Physicians Only

 

Prostate Cancer and supplementation
with alpha-tocopherol and beta-carotene:
incidence and mortality in a controlled trial



ABSTRACT:

BACKGROUND:

Epidemiologic studies have suggested that vitamin E and beta-carotene may each influence the development of prostate cancer. In the Alpha-Tocopherol, beta-carotene Cancer Prevention Study, a controlled trial, we studied the effect of alpha-tocopherol (a form of vitamin E) and beta-carotene supplementation, separately or together, on prostate cancer in male smokers.

METHODS:
A total of 29,133 male smokers aged 50-69 years from southwestern Finland were randomly assigned to receive alpha-tocopherol (50mg), beta-carotene 20mg., both agents, or placebo daily for 5-8 years (median, 6.1 years). The supplementation effects were estimated by a proportional hazards model, and two- sided P values were calculated.

RESULTS:
We found 246 new cases of and 62 deaths from prostate cancer during the follow-up period. A 32% decrease (95% confidence interval (CI)= -47% to 12%) in the incidence of prostate cancer was observed among the subjects receiving alpha-tocopherol (n=14564) compared with those not receiving alpha-tocopherol (n=14569). The reduction was evident in clinical prostate cancer but not in latent cancer. Mortality from prostate cancer was 41% lower (95% CI=-65% to 1%) among men receiving alpha-tocopherol. Among subjects receiving beta-carotene (n=14560), prostate cancer incidence was 23% higher (95% CI=30%-89%) compared with those not receiving beta-carotene. (n=14573). Neither agent had any effect on the time interval between diagnosis and death.

CONCLUSIONS:
Long-term supplementation with alpha-tocopherol substantially reduced prostate cancer incidence and mortality in male smokers.

Other controlled trials are required to confirm the findings.


Heinonen OP; Albanes D; Virtamo J; Taylor PR; Huttunen JK; Hartman AM; Haapakoski J; Malila N; Rautalahti M; Ripatti S; Maenpaa H; Teerenhovi L; Koss L; Virolainen M’ Edwards BK. Department of Public Health, University of Helsinki, Finland. J Natl Cancer Inst 1998 Mar 18;90(6):440-6. NLM CIT.ID:98180463. COMMENT: J Natl Cancer Inst 1998 Mar 18;90(6):414-5. J Natl Cancer Inst 1998 Mar 18;90(6):416-7.


Index of Articles






Site Navigation and Quick Links


HomeHealth ClubSite IndexLibraryPhysicians OnlyCheckout
VitaminsHerbsMinerals Amino AcidsEnzymesHormones
HomeopathicsAyurvedaGlandularsFatty AcidsXtra-Cell

Alphabetical Product IndexHealth Function Index
Condition Specific FormulasThe Latest Health Research

Frozen Cellular ExtractsXtra-CellTop Products
Optimum Health Essentials™Ultra Preventive X

Contact UsCustomer ServicePrivacy PolicyConditions Of Use
Pricing, Availability and ReturnsPrivacy Companies

Development Team

Comprehensive Blood Testing and Laboratory Services
Secure Private and Confidential Lab Testing

Doctor Morrow
About Dr Morrow
Healing from Within
The Power of Prayer
Prayer Requests

Featured Products
Featured Product
Top Products

Optimum Health EssentialsTM

Ultra Preventive X
Ultra Preventive IX

Traumeel

Wobenzym N

Manufacturers
BHI
Atrium
Douglas Laboratories
Heel
Metagenics
Nutrition Dynamics
Professional Health Products
Pure Encapsulations
Wobenzym

Checkout
Checkout
Physicians Checkout

Members
Member Zone

Physicians/Professionals/Affiliates
Signup
Lost PasswordEdit Profile


Nutrition Dynamics, Inc.• 510 West Court Street • Seguin, Texas 78155
Copyright © 1998-<%=Year(Now)%> • All Rights Reserved • Patent Pending
800.926.2906